Autoimmune Patients Face Higher Long COVID Risk

A new study reveals that individuals with rheumatic conditions are more likely to develop long COVID after infection.

Updated on Oct. 20, 2026 in Arthritis

Autoimmune Patients Face Higher Long COVID Risk

Live Poll

Do you feel new research on medical risks changes how you monitor your personal health?

Patients with autoimmune rheumatic diseases show an increased prevalence of long COVID compared to those without such conditions. Research published on October 14 indicates these patients face a 56 percent higher risk of developing persistent symptoms.

Why it matters

Understanding the elevated risk for patients with underlying autoimmune issues helps clinicians better identify those who may require specialized monitoring following a COVID-19 infection. The study highlights how specific pre-existing health statuses can influence the long-term impact of viral illnesses.

A study of 187,106 matched patients found long COVID occurred in 2.8 percent of those with autoimmune rheumatic diseases versus 1.5 percent of non-AIRD controls.

The players

Arthritis & Rheumatology

This is a peer-reviewed medical journal that publishes research related to the diagnosis and treatment of rheumatic diseases.

National Clinical Cohort Collaborative

This organization facilitates large-scale clinical data analysis by aggregating health records to support medical research.

The details

Researchers utilized 1:1 nearest-neighbor propensity score matching to compare patients with autoimmune conditions against non-affected controls. Factors including obesity, pulmonary disease, glucocorticoid exposure, and Sjögren syndrome were identified as contributors to the increased risk profile.

October 14, 2026: The study was published in the journal Arthritis & Rheumatology.
October 20, 2026: Publication date of the article.

The Big Picture

By leveraging the National Clinical Cohort Collaborative, this research advances our understanding of how chronic disease profiles interact with post-acute infection syndromes. It shifts focus from general population risks to the specific vulnerability of the immunocompromised community.

Patients diagnosed with rheumatic conditions may need to discuss personalized post-infection monitoring plans with their healthcare providers. Recognizing these risks allows for more proactive management of persistent symptoms should a COVID-19 infection occur.

The takeaway

Patients with autoimmune rheumatic diseases should be aware that their condition may complicate recovery from COVID-19. Proactive communication with a rheumatologist following an infection can help ensure any lingering symptoms are addressed promptly.